Humanization of rabbit antibodies using a universal antibody framework
US-11858981-B2 · Jan 2, 2024 · US
Methods for treating medical conditions by anti-type 2 therapy
US10654923B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10654923-B2 |
| Application number | US-201615387324-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 21, 2016 |
| Priority date | Dec 28, 2015 |
| Publication date | May 19, 2020 |
| Grant date | May 19, 2020 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This document provided methods and materials involved in treating medical conditions. For example, methods and materials for using anti-Interleukin 4, anti-Interleukin 5, and/or anti-Interleukin 13 antibodies to treat asthma in a mammal identified as having a Th2 immune response using a whole blood cell-based cytokine whole blood cell-based cytokine assay are provided.
First claim
Opening claim text (preview).
What is claimed is: 1. A method for treating a medical condition in a human, wherein said method comprises administering an anti-type 2 therapy to a human identified as having an Interleukin 4 to Interleukin 2 ratio in a whole blood cell based cytokine assay greater than 0.4, wherein the severity of said medical condition within said human is reduced. 2. The method of claim 1 , wherein said medical condition is asthma. 3. The method of claim 1 , wherein said anti-type 2 cytokine therapy is an anti-Interleukin 4 antibody therapy, an anti-Interleukin 5 antibody therapy, or an anti-Interleukin 13 antibody therapy.
Assignees
Inventors
Classifications
IFN-gamma · CPC title
Chronic or obstructive airway disorders, e.g. asthma COPD · CPC title
Bowel diseases, e.g. Crohn, ulcerative colitis, IBS · CPC title
Interleukins [IL] · CPC title
Interleukins [IL] · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10654923B2 cover?
- This document provided methods and materials involved in treating medical conditions. For example, methods and materials for using anti-Interleukin 4, anti-Interleukin 5, and/or anti-Interleukin 13 antibodies to treat asthma in a mammal identified as having a Th2 immune response using a whole blood cell-based cytokine whole blood cell-based cytokine assay are provided.
- Who is the assignee on this patent?
- Mayo Found Medical Education & Res
- What technology area does this patent fall under?
- Primary CPC classification C07K16/241. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue May 19 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).